This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Epizyme, Inc.
Sponsor:
Information provided by (Responsible Party):
Epizyme, Inc.
ClinicalTrials.gov Identifier:
NCT02601950
First received: October 21, 2015
Last updated: May 16, 2017
Last verified: May 2017
  Purpose

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID administered orally in continuous 28 day cycles. Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. Eligible subjects will be enrolled into one of fivecohorts based on tumor type:

  • Cohort 1: MRT, RTK, ATRT, or selected tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO]
  • Cohort 2: Relapsed or refractory synovial sarcoma with SS18-SSX rearrangement
  • Cohort 3: Other INI1 negative tumors or any solid tumor with an EZH2 gain of function (GOF) mutation, including: epithelioid malignant peripheral nerve sheath tumor (EMPNST), extraskeletal myxoid chondrosarcoma (EMC), myoepithelial carcinoma, other INI1-negative malignant tumors with Sponsor approval (e.g., dedifferentiated chordoma) any solid tumor with an EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma
  • Cohort 4: Renal medullary carcinoma (RMC)
  • Cohort 5: Epithelioid sarcoma (ES)

Treatment with tazemetostat will continue until disease progression, unacceptable toxicity or withdrawal of consent, or termination of the study. Response assessment will be evaluated after 8 weeks of treatment and then every 8 weeks thereafter while on study.


Condition Intervention Phase
Malignant Rhabdoid Tumors (MRT) Rhabdoid Tumors of the Kidney (RTK) Atypical Teratoid Rhabdoid Tumors (ATRT) Selected Tumors With Rhabdoid Features Synovial Sarcoma INI1-negative Tumors Malignant Rhabdoid Tumor of Ovary Renal Medullary Carcinoma Epithelioid Sarcoma Any Solid Tumor With an EZH2 GOF Mutation Drug: Tazemetostat Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Resource links provided by NLM:


Further study details as provided by Epizyme, Inc.:

Primary Outcome Measures:
  • Number of subjects with objective response using disease appropriate standardized response criteria [ Time Frame: Assessed every 8 weeks for duration of study participation which is estimated to be 24 months ]
  • Progression-free survival (PFS) rate for Cohort 2 (Relapsed/Refractory Synovial Sarcoma) [ Time Frame: 16 weeks of treatment ]
    The number of subjects with CR, PR, or stable disease (SD) at 16 week assessment

  • Disease control rate (DCR) in subjects in Cohort 5 (Epithelioid Sarcoma) following oral administration of tazemetostat 800 mg BID [ Time Frame: 32 weeks of treatment ]
    The number of subjects with a confirmed CR or PR, or SD at 32 week assessment


Secondary Outcome Measures:
  • 1. Overall response rate ORR for Cohort 2 (relapsed/refractory synovial sarcoma) and Cohort 5 (epithelioid sarcoma) [ Time Frame: Assessed every 8 weeks for duration of study participation which is estimated to be 24 months ]
    ORR (confirmed CR+PR, RECIST 1.1)

  • PFS for each cohort [ Time Frame: 24, 32 and 56 weeks of treatment ]
    The time from date of first dose of study treatment to the earlier of the date of first documented disease progression or date of death due to any cause

  • OS for each cohort [ Time Frame: 24, 32 and 56 weeks of treatment ]
    The time from the date of the first dose of study treatment to the date of death due to any cause

  • Response duration for each cohort and Cohorts 1, 3, 4 and 5 combined [ Time Frame: Every 8 weeks until disease progression or start of new anti-cancer therapy ]
  • Incidence of treatment-emergent adverse events as a measure of safety and tolerability [ Time Frame: Adverse events assessed from first dose through 30 days post last dose ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Cmax [ Time Frame: Days 1 and 15 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Tmax [ Time Frame: Days 1 and 15 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): AUC(0-t) [ Time Frame: Days 1 and 15 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): AUC(0-12) [ Time Frame: Days 1 and 15 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): t1/2 [ Time Frame: Days 1 and 15 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): CL/F [ Time Frame: Days 1, 15, 29, 43, and 57 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Vd/F [ Time Frame: Days 1, 15, 29, 43, and 57 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Ka [ Time Frame: Days 1, 15, 29, 43, and 57 ]
  • Pharmacokinetics profile of tazemetotstat and its metabolite (plasma): Ctrough [ Time Frame: Days 29, 43 and 57 ]
  • Investigate the pharmacodynamics (PD) effects of tazemetostat in tumor tissue [ Time Frame: At week 8 ]
    IHC assessments of changes in the level of H3K27-Me3 following tazemetostat dosing


Estimated Enrollment: 180
Study Start Date: December 2015
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Open-label Tazemetostat
All Cohorts [Cohort 1 - MRT, RTK, ATRT, or tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO] Cohort 2 - Relapsed/refractory synovial sarcoma (SS18-SSX rea), Cohort 3 - Other INI1-negative tumors or any solid tumor with an EZH2 GOF mutation, Cohort 4 - Renal medullary carcinoma and Cohort 5 - Epithelioid sarcoma] will receive 800 mg oral Tazemetostat BID x 28 days
Drug: Tazemetostat
Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Other Names:
  • EPZ-6438
  • E7438

  Eligibility

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age (at the time of consent/assent): ≥16 years of age
  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  3. Has a life expectancy of >3 months
  4. Has a malignancy:

    • For which there are no standard therapies available (Cohorts 1, 3, 4 and 5)
    • That is relapsed or refractory after treatment with an approved therapy(ies), defined as metastatic or non-resectable, locally advanced disease that has previously been treated with and progressed following approved therapy(ies) (Cohort 2)

      • That has progressed within 6 months prior to study enrollment (Cohort 5 Expansion ONLY)
  5. Has a documented local diagnostic pathology of original biopsy confirmed by a Clinical Laboratory Improvement Amendments (CLIA/College of American Pathologists (CAP) or equivalent laboratory certification
  6. For Cohort 1 (rhabdoid tumors only), the following test results must be available by local laboratory: morphology and immunophenotypic panel consistent with rhabdoid tumors, and loss of INI1 or SMARCA4 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 or SMARCA4 loss or mutation when INI1 or SMARCA4 IHC is equivocal or unavailable
  7. For Cohort 2 (subjects with relapsed/refractory synovial sarcoma only), the following tests must be available by local laboratory: Morphology consistent with synovial sarcomas, and cytogenetics or fluorescence in situ hybridization (FISH) and/or molecular confirmation (e.g., DNA sequencing) of SS18 rearrangement t(X;18)(p11;q11)
  8. For Cohort 3 to 5 (subjects with INI1-negative/aberrant tumors or any solid tumor with EZH2 GOF mutation only), the following test results must be available by local laboratory: Morphology and immunophenotypic panel consistent with INI1-negative tumors (not applicable for solid tumors with EZH2 GOF mutation), and loss of INI1 confirmed by IHC, or molecular confirmation of tumor bi-allelic INI1 loss or mutation when INI1 IHC is equivocal or unavailable, or molecular evidence of EZH2 GOF mutation
  9. Prior therapy(ies), if applicable, must be completed according to the criteria below:

    • Chemotherapy: cytotoxic (At least 21 days since last dose of chemotherapy prior to first dose of tazemetostat)
    • Chemotherapy: nitrosoureas (At least 6 weeks since last dose of nitrosoureas prior to first dose of tazemetostat)
    • Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least 14 days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat)
    • Monoclonal antibody(ies) (At least 3 half-lives since the last dose of any monoclonal antibody prior to first dose of tazemetostat)
    • Immunotherapy (e.g. tumor vaccine) (At least 42 days since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)
    • Radiotherapy (RT) (At least 14 days from last local site RT prior to first dose of tazemetostat/At least 21 days from stereostatic radiosurgery prior to first dose of tazemetostat/At least 12 weeks from craniospinal, ≥50% radiation of pelvis, or total body irradiation prior to first dose of tazemetostat)
    • High dose therapy with autologous hematopoietic cell infusion (At least 60 days from last infusion prior to first dose of tazemetostat)
    • Hematopoietic growth factor (At least 14 days from last dose of hematopoietic growth factor prior to first dose of tazemetostat)
  10. Has sufficient tumor tissue (slides or blocks) available for central confirmatory testing of IHC and/or cytogenetics/FISH and/or DNA mutation analysis (required for study entry but enrollment based on local results)
  11. Has measurable disease based on either RECIST 1.1 for solid tumors or RANO for CNS tumors
  12. Has adequate hematologic (bone marrow [BM] and coagulation factors), renal and hepatic function as defined by criteria below:

    • Hematologic (BM Function):

      • Hemoglobin ≥9 mg/dL
      • Platelets ≥100,000/mm^3 (≥100x10^9/L)
      • ANC ≥1,000/mm^3 (≥1.0x10^9/L)
    • Hematologic (Coagulation Factors):

      • PT and PTT <1.5 ULN
      • Fibrinogen >0.5 LLN
    • Renal Function:

      - Serum creatinine ≤1.5 x ULN

    • Hepatic Function:

      • Conjugated bilirubin <1.5 x ULN
      • AST and ALT <3 x ULN
  13. For subjects with ATRT only, subject must have seizures that are stable, not increasing in frequency or severity and controlled on current anti-seizure medication(s) for a minimum of 21 days prior to the planned first dose of tazemetostat
  14. Has a shortening fraction of >27% or an ejection fraction of ≥50% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan and New York Heart Association (NYHA) Class ≤2
  15. Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec

Exclusion Criteria:

  1. Has had prior exposure to tazemetostat or other inhibitor(s) of enhancer of zeste homologue-2 (EZH2)
  2. Has participated in another interventional clinical study and received investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the planned first dose of tazemetostat
  3. Has known active CNS or any leptomeningeal metastasis of primary extra-cranial tumor - NOTE: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging 4 weeks prior to the first dose of study drug and any neurologic symptoms have stabilized), have no evidence of new or enlarging brain metastases, and are on stable or tapering doses of steroids for at least 7 days prior to first dose of study drug.
  4. Has had a prior malignancy other than the malignancies under study - EXCEPTION: A subject who has been disease-free for 5 years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible
  5. Has had major surgery within 3 weeks prior to enrollment
  6. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
  7. Has cardiovascular impairment, history of congestive heart failure greater than NYHA Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment
  8. Is currently taking any prohibited medication(s)
  9. Has an active infection requiring systemic treatment
  10. Is immunocompromised (i.e. has congenital immunodeficiency), including subjects known history of infection with human immunodeficiency virus (HIV)
  11. Has known chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (detectable HCV RNA)
  12. Has had a symptomatic venous thrombosis within the 3 months prior to study enrollment - NOTE: Subjects with a history of a deep vein thrombosis >2 weeks prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study
  13. For subjects with CNS involvement (primary tumor or metastatic disease), have any active bleeding or new intratumoral hemorrhage of more than punctuate size of screening MRI obtained within 14 days of starting study drug or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02601950

Contacts
Contact: Maria Roche, NP 855-500-1011 clinicaltrials@epizyme.com
Contact: Peter Ho, MD, PhD 855-500-1011 clinicaltrials@epizyme.com

  Show 33 Study Locations
Sponsors and Collaborators
Epizyme, Inc.
  More Information

Responsible Party: Epizyme, Inc.
ClinicalTrials.gov Identifier: NCT02601950     History of Changes
Other Study ID Numbers: EZH-202
Study First Received: October 21, 2015
Last Updated: May 16, 2017

Additional relevant MeSH terms:
Neoplasms
Sarcoma
Sarcoma, Synovial
Rhabdoid Tumor
Carcinoma, Medullary
Kidney Neoplasms
Ovarian Neoplasms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Neoplasms, Complex and Mixed
Carcinoma, Neuroendocrine
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms, Ductal, Lobular, and Medullary
Neoplasms, Nerve Tissue
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female

ClinicalTrials.gov processed this record on July 27, 2017